Drug Patents owned by Progenics Pharms Inc

1. Drug name - PYLARIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(5 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(6 years from now)

US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(7 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(14 years from now)

CN103922998A PROGENICS PHARMS INC Heterogeneous Dimer Of Glutamic Acid
May, 2017

(5 years ago)

CN101778910A PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

CN101778910B PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

CN102171187A PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

CN102171187B PROGENICS PHARMS INC Psma- Binding Agent And Use Thereof
Jul, 2029

(6 years from now)

CN107382846B PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

CN107382846A PROGENICS PHARMS INC Psma- Binding Agent And Use Thereof
Jul, 2029

(6 years from now)

IN315927B PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP3335736A1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Jun, 2022

(3 months ago)

EP3335736B1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Jun, 2022

(3 months ago)

EP2942065A1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP2942065B1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP2097111A2 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP2097111A4 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP3699162B1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP3699162A1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP2097111B1 PROGENICS PHARMS INC Heterodimers Of Glutamic Acid
Nov, 2027

(5 years from now)

EP2318366A2 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP2318366A4 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP2318366B1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP3222615B1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP3222615A1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50ML (1-80mCi/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.